GT Biopharma, Inc.

As of March 31, 2026, GT Biopharma, Inc. has 35.18M shares outstanding.

As of March 31, 2026, GT Biopharma, Inc. maintains a current ratio of 4.14, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, GT Biopharma, Inc. posted a negative return on equity (ROE) of -1,959.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -754.45, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -1,036.73, pointing to unprofitable operations over the period.

These figures cover the twelve months ended March 31, 2026. The dividend payout ratio of 0.58 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

GT Biopharma, Inc.'s most recent stock split took place on February 11, 2021 with a 17:1 split ratio.

As of March 31, 2026, GT Biopharma, Inc. has an Altman Z-Score of -105.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.